ArticleBMC complementary and alternative medicine2012
Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro.
Article in BMC complementary and alternative medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- A systematic review of anticancer effects of radix astragali.Chinese journal of integrative medicine · 2016Pooled it
- Effect of decoction of Fuzheng Jiedu Xiaoji formula plus chemoembolization on primary liver cancer in patients.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Trial
- Review
- Efficacy and potential mechanism of main active ingredients ofTranslational cancer research · 2026Article
- Physicochemical characteristics and anti-colorectal cancer activity ofFrontiers in nutrition · 2026Article
- Recent Advances in the Mechanisms and Applications ofMolecules (Basel, Switzerland) · 2025Review
- Mechanisms of drug resistance in hepatocellular carcinoma.Biological procedures online · 2025Review
- Astragalus polysaccharides: structure-immunomodulation relationships, multi-target pharmacological activities, and cutting-edge applications in immune modulation.Frontiers in immunology · 2025Review
- Recent efficacy and long-term survival ofWorld journal of clinical oncology · 2024Article
- Anticancer Mechanism ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Synergist for antitumor therapy: Astragalus polysaccharides acting on immune microenvironment.Discover oncology · 2023Review
- Polysaccharides from Chinese herbs as natural weapons against colorectal cancer.Bioscience reports · 2023Review
- Effect ofFrontiers in pharmacology · 2023Article
- A network pharmacology approach for investigating the multi-target mechanisms of Huangqi in the treatment of colorectal cancer.Translational cancer research · 2021Article
- Article
- Interaction between phytotherapy and oral anticancer agents: prospective study and literature review.Medical oncology (Northwood, London, England) · 2019Review
- Traditional Chinese medicineOncoTargets and therapy · 2018Article
- Recent Advances in Herbal Medicines for Digestive System Malignancies.Frontiers in pharmacology · 2018Review
- Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication.Microbial pathogenesis · 2018Article
- Astragalus polysaccharides exerts immunomodulatory effects via TLR4-mediated MyD88-dependent signaling pathway in vitro and in vivo.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAstragalus polysaccharides (APS) are active constituents of Astragalus membranaceus. They have been widely studied, especially with respect to their immunopotentiating properties, their ability to counteract the side effects of chemotherapeutic drugs, and their anticancer properties. However, the mechanism by which APS inhibit cancer and the issue of whether that mechanism involves the reversal of multidrug resistance (MDR) is not completely clear. The present paper describes an investigation of the effects of APS on P-glycoprotein function and expression in H22 hepatoma cell lines resistant to Adriamycin (H22/ADM).
methodsH22/ADM cell lines were treated with different concentrations of APS and/or the most common chemotherapy drugs, such as Cyclophosphamid, Adriamycin, 5-Fluorouracil, Cisplatin, Etoposide, and Vincristine. Chemotherapeutic drug sensitivity, P-glycoprotein function and expression, and MDR1 mRNA expression were detected using MTT assay, flow cytometry, Western blotting, and quantitative RT-PCR.
resultsWhen used alone, APS had no anti-tumor activity in H22/ADM cells in vitro. However, it can increase the cytotoxicity of certain chemotherapy drugs, such as Cyclophosphamid, Adriamycin, 5-Fluorouracil, Cisplatin, Etoposide, and Vincristine, in H22/ADM cells. It acts in a dose-dependent manner. Compared to a blank control group, APS increased intracellular Rhodamine-123 retention and decreased P-glycoprotein efflux function in a dose-dependent manner. These factors were assessed 24 h, 48 h, and 72 h after administration. APS down regulated P-glycoprotein and MDR1 mRNA expression in a concentration-dependent manner within a final range of 0.8-500 mg/L and in a time-dependent manner from 24-72 h.
conclusionAPS can enhance the chemosensitivity of H22/ADM cells. This may involve the downregulation of MDR1 mRNA expression, inhibition of P-GP efflux pump function, or both, which would decrease the expression of the MDR1 protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.